Journal
AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 165, Issue -, Pages 115-124Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2016.02.025
Keywords
-
Categories
Funding
- NIH/NEI [K23EY022949]
- NATIONAL INSTITUTES OF HEALTH (NIH), BETHESDA
- (Building Interdisciplinary Research Career in Women's Health, National Institute of Child Health and Human Development and Office of Research on Women's Heath), NIH, Bethesda [K12FID055892]
- NIH, Bethesda [AG12975, DK60753, R01 EY015473]
- Komarek-Hyde-McQueen Foundation Glaucoma Research Fund
- Research to Prevent Blindness at the Illinois Eye and Ear Infirmary, NIH, Bethesda [P30 EY001792]
- University of Illinois at Chicago Center for Clinical and Translational Science (CCTS) [ULITR000050]
- National Center for Advancing Translational Sciences, Bethesda
- Harvard Medical Scholar Distinguished Ophthalmology Scholar award, Boston
Ask authors/readers for more resources
PURPOSE: Previous studies suggest that hormone therapy favorably affects intraocular pressure (IOP). Here, we examined the association between hormone therapy use and KW in the context of a large randomized trial. DESIGN: Secondary data analysis from a randomized controlled trial. METHODS: We used data from the Women's Health Initiative-Sight Exam (WHISE). Women with prior hysterectomy received oral conjugated equine estrogen (0.625 mg/day) or placebo. Women with a uterus received estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/day) or placebo. IOP was measured 5 years after randomization. Adjusted linear regression models were used to assess the association between hormone therapy and IOP. RESULTS: The WHISE included 1668 women in the estrogen-alone trial (aged 63-86, mean 72 years) and 2679 women in the estrogen-plus-progestin trial (aged 63-87, mean 72 years). In multivariate analyses, compared to placebo treatment, treatment with estrogen alone was associated with a 0.5 mm Hg reduction of the IOP in the right eye (95% CI: -0.8, -0.1, P = .005) and a 0.6 mm Hg (95% CI: -0.9, -0.3, P < .001) reduction of the IOP in the left eye. In the estrogen-plus-progestin trial, there was no significant difference in IOP between the treatment and placebo groups (P = .30 right eye and P = .43 left eye). CONCLUSIONS: This study represents an IOP analysis in the largest hormone trial available. Estrogen-alone therapy in postmenopausal women is associated with a small but significant IOP reduction of 0.5 mm Hg. The clinical significance of this small decrease remains to be determined. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available